Conclusions
In conclusion, GH supplementation during OS is associated with a significantly increased probability of obtaining euploid blastocysts in women aged 38–40 years, but this benefit is not significant in patients aged 41–46 years. Our results might be helpful for AMA patients undergoing PGT-A cycles to obtain a better outcome and meanwhile to avoid over-treatment. Future RCTs are needed to confirm our results and the effect of GH in women aged ≥ 41 years requires further investigation.